Abstract
Deubiquitinating enzymes (DUBs) are a novel "drug-able" target for cervical cancer, and small-molecule inhibitors of DUBs are currently being evaluated as novel chemotherapeutic agents. In this chapter, we describe an enzyme activity assay to assess the selectivity of a putative small-molecule DUB inhibitor toward a subset of DUBs in cancer cell lines.
| Original language | English (US) |
|---|---|
| Title of host publication | Cervical Cancer |
| Subtitle of host publication | Methods and Protocols |
| Publisher | Springer New York |
| Pages | 193-200 |
| Number of pages | 8 |
| ISBN (Electronic) | 9781493920136 |
| ISBN (Print) | 9781493920129 |
| DOIs | |
| State | Published - Oct 27 2014 |
Bibliographical note
Publisher Copyright:© Springer Science+Business Media New York 2015. All rights are reserved.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Cervical cancer
- Cysteine proteases
- Deubiquitinating enzymes
- Dub
- Ha-ub-vs probe
- Metalloproteases
- P53
- Protease inhibitors
- Proteases
- Proteasome
- Ubiquitin
Fingerprint
Dive into the research topics of 'Measurement of deubiquitinating enzyme activity via a suicidal HA-Ub-VS probe'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS